Cationic Lipid mRNA Transfection Composition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for transfecting mRNA into cells face challenges such as high cytotoxicity, immune activation, and inefficient delivery, particularly for hard-to-transfect cells and in vivo applications, due to limitations in cationic lipid formulations and polymer systems.

Innovation Solution

A composition comprising a mRNA, a neutral lipid, and a cationic lipid of specific formula, formulated as small-sized liposomes with a controlled surface charge density and fusogenic activity, is used to enhance transfection efficiency and reduce immune activation by stabilizing the mRNA and facilitating endosomal escape.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If cationic lipid formulations or polymer systems are used to transfect mRNA into cells, then transfection efficiency is improved, but cytotoxicity increases

Engineering Contradiction:

Improvetransfection efficiencyVSAvoidcytotoxicity

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical structure of cationic lipids by varying the hydrophobic chain length (R2, R3, R4, R5) and the spacer length ((CH2)n) to optimize the balance between transfection efficiency and cytotoxicity. By systematically changing these parameters, the invention identifies lipid structures that achieve effective mRNA delivery with reduced cellular toxicity compared to conventional cationic lipids.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent formulates composite lipid compositions containing multiple cationic lipids with different hydrophobic chain configurations, along with neutral lipids and cholesterol. This composite approach allows the formulation to combine the benefits of different lipid structures, achieving both high transfection efficiency and reduced cytotoxicity through synergistic effects among the components.

Inventive Principle:

Principle #40Composite materials

2Productivity

If exogenous mRNA is introduced into mammalian cells, then protein expression is achieved, but immune activation occurs

Engineering Contradiction:

Improveprotein expressionVSAvoidimmune activation

Core Design Contradiction:

ProductivityVSObject-generated harmful factors

Solution Approach 1:

The patent exploits the natural cationic charge of cell membranes and endosomal membranes to facilitate mRNA delivery. The cationic lipids bind to the negative phosphate groups of mRNA and interact with negative charges on endosomal membranes, converting the potentially harmful immune recognition of exogenous mRNA into a beneficial mechanism for cellular uptake and endosomal escape that reduces immune activation.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Productivity

If current transfection methods are used for hard-to-transfect cells, then some protein expression is achieved, but transfection efficiency is insufficient

Engineering Contradiction:

Improveprotein expressionVSAvoidtransfection efficiency

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent optimizes multiple parameters including the cationic to neutral lipid ratio, the hydrophobic chain length of cationic lipids, and the spacer length between the cationic headgroup and hydrophobic chains. These parameter optimizations are specifically tailored to overcome the membrane resistance of hard-to-transfect cells, achieving reliable and efficient protein expression in cell types that are resistant to conventional transfection methods.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition achieves efficient and safe mRNA delivery into mammalian cells, reducing cytotoxicity and immune response, while enabling transient protein expression for various applications including gene editing and vaccination.

Implementation Method 1

formulated as small-sized liposomes with a controlled surface charge density

Methodology Applied

Scientific EffectLiposome formation: Amphiphiles

Implementation Method 2

fusogenic activity, is used to enhance transfection efficiency and reduce immune activation by stabilizing the mRNA and facilitating endosomal escape

Methodology Applied

Scientific EffectFusion:

Data Source

PatentEP3646854B1Compositions for transfecting mRNA into a cell and their applications

Publication Date: 2022.08.03 POLYPLUS TRANSFECTION SA

Figure 1~2
Figure 3~4

AI summary

The present invention relates to compositions for transfecting a messenger RNA (mRNA) into a cell and their applications. The present invention is directed to a composition for transfecting a mRNA into a cell comprising a mRNA, at least one neutral lipid and a cationic lipid of formula (I), wherein R1 R2, R3, R4 and R5, (CH2)n and A- are as defined in the description. The present invention also relates to uses of said composition and to a method for in vitro transfection of live cells.